Alumis: LUMUS Phase 2b lupus trial misses primary and secondary endpoints overall
Alumis said its Phase 2b LUMUS trial of envudeucitinib in systemic lupus erythematosus did not meet its primary or secondary endpoints in the overall population of 408 patients. The company highlighted a prespecified subgroup with high interferon gene signature, where responses were robust, and plans to engage regulators on Phase 3 development, while its planned NDA for psoriasis remains on track for the fourth quarter of 2026.
Key points
- LUMUS enrolled 408 patients; the primary endpoint, BICLA at Week 48, was not met in the overall trial population.
- In the prespecified IFNGS-high subgroup, BICLA response was 52.6% on 40mg twice-daily versus 28.6% on placebo.
- Alumis plans an end-of-Phase 2 meeting with the FDA and EMA to discuss Phase 3 development in SLE.
- The NDA for envudeucitinib in moderate-to-severe plaque psoriasis remains planned for the fourth quarter of 2026.
The filing
Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 01, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.